Wangzhi Li
Stock Analyst at Ladenburg Thalmann
(3.04)
# 1,350
Out of 4,711 analysts
5
Total ratings
80%
Success rate
51.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Wangzhi Li
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BGNE BeiGene | Upgrades: Buy | $278 | $176.50 | +57.51% | 2 | Dec 8, 2020 | |
| KRYS Krystal Biotech | Initiates: Buy | $23 | $164.83 | -86.05% | 1 | Oct 18, 2017 | |
| LPTX Leap Therapeutics | Initiates: Buy | $180 | $2.91 | +6,085.57% | 1 | Mar 7, 2017 | |
| CLRB Cellectar Biosciences | Initiates: Buy | $270 | $0.24 | +114,793.62% | 1 | Dec 21, 2016 |
BeiGene
Dec 8, 2020
Upgrades: Buy
Price Target: $278
Current: $176.50
Upside: +57.51%
Krystal Biotech
Oct 18, 2017
Initiates: Buy
Price Target: $23
Current: $164.83
Upside: -86.05%
Leap Therapeutics
Mar 7, 2017
Initiates: Buy
Price Target: $180
Current: $2.91
Upside: +6,085.57%
Cellectar Biosciences
Dec 21, 2016
Initiates: Buy
Price Target: $270
Current: $0.24
Upside: +114,793.62%